Jan 9 (Reuters) - Eyegate Pharmaceuticals Inc EYEG.O
* Eyegate receives additional milestone payment from Valeant Pharmaceuticals (NYSE:VRX) for EGP-437
* Remain on track to submit NDA for potential FDA approval of EGP-437 in Uveitis by end of year Source text for Eikon: ID:nGNXNNVHYa Further company coverage: EYEG.O